Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 141Lung Neoplasms 51Pancreatic Neoplasms 30Non-Squamous Non-Small Cell Lung Cancer 18Neoplasms 15Adenocarcinoma of Lung 14Head and Neck Neoplasms 13Glioblastoma 13Gliosarcoma 12Breast Neoplasms 11Brain Neoplasms 11Neoplasm Metastasis 9Carcinoma, Hepatocellular 9Adenocarcinoma, Bronchiolo-Alveolar 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Squamous Cell 7Carcinoma, Renal Cell 7Astrocytoma 6Oligodendroglioma 5Carcinoma 5Urinary Bladder Neoplasms 4Liver Neoplasms 4Glioma 4Esophageal Neoplasms 4Colorectal Neoplasms 4Adenocarcinoma 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3

Interventions

Tretinoin 5Methotrexate 5Tacrolimus 4Arsenic Trioxide 4fludarabine phosphate 3Peripheral Blood Stem Cell Transplantation 3Busulfan 3Mycophenolic Acid 2Mercaptopurine 2Idarubicin 2Gemtuzumab 2Filgrastim 2Cytarabine 2Cyclophosphamide 2Antilymphocyte Serum 2thymoglobulin 1entinostat 1Whole-Body Irradiation 1Vorinostat 1Sorafenib 1Sirolimus 1Granulocyte Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Daunorubicin 1Clofarabine 1Bortezomib 1Biopsy 1Azacitidine 1Alemtuzumab 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Promyelocytic, Acute × Erlotinib Hydrochloride × Clear all
NCT01664897 2020-01-07

Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Completed
29 enrolled 11 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡